Skip to content

Apical Suspension Repair for Vault Prolapse In a Three-Arm Randomized Trial Design

Three Arm Apical Suspension Trial for Post-Hysterectomy Vault Prolapse: Prospective Randomized Trial Involving Sacral Colpopexy, Transvaginal Mesh and Native Tissue Apical Repair

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02676973
Acronym
ASPIRe
Enrollment
360
Registered
2016-02-09
Start date
2016-02-29
Completion date
2026-12-31
Last updated
2026-09-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Visceral Prolapse

Keywords

pelvic organ prolapse, POP, vault prolapse, cystocele, vaginal prolapse, post-hysterectomy vaginal prolapse

Brief summary

The study is a multi-center, randomized, surgical trial of women with symptomatic post-hysterectomy apical (cuff) prolapse desiring surgical treatment. This study will compare the three available surgical treatments performed in usual practice. The purpose of this study is to compare two commonly performed mesh apical repair (sacral colpopexy vs. Apical Transvaginal Mesh) and vaginal native tissue apical repairs with mesh reinforced repairs. The primary outcome is measured over time (up to 60 months) using a survival analysis approach. Participants will be followed for at least 36-months (3-years) post surgery and up to a maximum of 60-months (5-years) during the primary trial. Participants who complete the primary trial will be approached for consent for long-term follow-up as part of a study extension and will be followed up to a maximum of 120-months (10-years). The investigators hypothesize that treatment failure will not differ between vaginally and abdominally placed mesh for vault vaginal prolapse, and mesh repairs (regardless of route of implantation) will be superior to native tissue apical suspension.

Detailed description

The primary purpose of this three arm randomized clinical trial is to determine if apical transvaginal mesh placement is non-inferior to sacral colpopexy for anatomic correction of post-hysterectomy vaginal vault prolapse and to determine if mesh reinforced repairs performed by abdominal or vaginal approach are superior to native tissue vaginal repair. This trial has the following primary aims: 1\. To determine if Apical Transvaginal Mesh is non-inferior to Sacral Colpopexy for anatomic correction of post-hysterectomy vaginal vault prolapse at time points through 3 years. 1A. In the case where Apical Transvaginal Mesh is shown to be statistically significantly non-inferior to Sacral Colpopexy for anatomic correction of post-hysterectomy vaginal vault prolapse at time points through 3 years, to determine if Apical Transvaginal Mesh is superior to Sacral Colpopexy for anatomic correction of post-hysterectomy vaginal vault prolapse at time points through 3 years. 2\. To determine if Sacral Colpopexy is superior to Native Tissue Repair for anatomic correction of post-hysterectomy vaginal vault prolapse at time points through 3 years. 3\. To determine if Apical Transvaginal Mesh is superior to Native Tissue Repair for anatomic correction of post-hysterectomy vaginal vault prolapse at time points through 3 years. Additional secondary aims include: 1. Evaluate the development of a valid and reliable Global Composite Outcome that balances adverse events and patient-centered outcomes to anatomic definitions of failure and success. 2. Determine the impact of preoperative frailty and mobility on surgical treatment outcomes and postoperative complications of older women following surgical correction of apical pelvic organ prolapse. 3. Evaluate the patient's perspective about adverse events and their role in patient decision-making outcomes. The aims include comparing patient versus surgeon rankings of complication grade, outcome, expectedness and seriousness, to estimate the association between patient rankings of adverse events (AEs) with decision-making and quality of life outcomes and to determine if their perspective about AEs changes over time.

Interventions

PROCEDUREOpen, Robotic, or Laparoscopic

Sacral Colpopexy is a surgery performed either through an incision in the abdomen or through several small incisions with the help of a laparoscope (a slender tube) or robot. The surgery is done with a permanent synthetic (man-made) mesh. The mesh is sutured (stitched) to the vagina and sacrum (tail bone) and is used as reinforcement. It provides additional support to weakened tissues and/or muscles.

PROCEDURETransvaginal Native Tissue Repair

Transvaginal Native Tissue Repair is a surgery performed with an incision through the vagina (transvaginal). The surgery is done using both permanent and absorbable sutures (stitches), to support weakened tissue and/or muscles, and attach the top of the vagina to ligaments in the pelvis (either to the sacrospinous ligament or uterosacral ligament).

PROCEDUREUphold™ LITE

Transvaginal Mesh Repair is a surgery performed with an incision through the vagina (transvaginal). The surgery is done with a permanent synthetic (man-made) mesh. The mesh is attached to ligaments in the pelvis and is used to reinforce natural tissue and/or muscles, which are no longer able to provide support to the vagina.

Sponsors

NICHD Pelvic Floor Disorders Network
Lead SponsorNETWORK
The Cleveland Clinic
CollaboratorOTHER
University of Alabama at Birmingham
CollaboratorOTHER
University of California, San Diego
CollaboratorOTHER
Duke University
CollaboratorOTHER
University of New Mexico
CollaboratorOTHER
Women and Infants Hospital of Rhode Island
CollaboratorOTHER
RTI International
CollaboratorOTHER
University of Pennsylvania
CollaboratorOTHER
University of Pittsburgh
CollaboratorOTHER
Kaiser Permanente
CollaboratorOTHER
University of Texas Southwestern Medical Center
CollaboratorOTHER
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
CollaboratorNIH

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Outcomes Assessor)

Eligibility

Sex/Gender
FEMALE
Age
21 Years to No maximum
Healthy volunteers
No

Inclusion criteria

1. Women age 21 or older 2. Prior total hysterectomy (no cervix present) 3. Prolapse beyond the hymen (defined as Ba, C, or Bp \> 0 cm) 4. Vaginal cuff descent into at least the lower two thirds of the vagina (defined as point C\> -2/3 TVL) 5. Bothersome bulge symptoms as indicated on question 3 of the PFDI-20 form relating to 'sensation of bulging' or 'something falling out' 6. Desires surgical treatment for post-hysterectomy vaginal prolapse 7. Available for up to 60 month follow-up

Exclusion criteria

1. Previous synthetic material or biologic grafts (placed vaginally or abdominally) to augment POP repair including anterior, posterior and/or apical compartments 2. Known previous formal SSLS performed for either uterovaginal or post-hysterectomy vaginal vault prolapse \* 3. Known adverse reaction to synthetic mesh or biological grafts; these complications include but are not limited to erosion, fistula, or abscess 4. Unresolved chronic pelvic pain-active 5. Prior abdominal or pelvic radiation 6. Contraindication to any of the index surgical procedures * Known Horseshoe Kidney or Pelvic Mass overlying the sacrum * Active diverticular abscess or active diverticulitis * Shortened vaginal length (\<6 cm TVL) * NOTE: * Only documented SSLS will be an exclusion. * Mesh used for only mid-urethral sling will NOT be an exclusion * If prior POP repair is unknown and unable to be documented, subjects will be eligible based on clinician judgment. The investigator will examine and assess for evidence of mesh or graft if no evidence of mesh or graft is present on examination subject remains eligible.

Design outcomes

Primary

MeasureTime frameDescription
Number of Participants Considered Failures6 months through 60 MonthsFailure was defined as any of the following: retreatment for prolapse, any POP-Q measure beyond the hymen, or presence of bother on PFDI vaginal bulge question. Under the permanent failure state assumption, the number of participants shown at each visit includes all participants who were still participating in the study or had a failure outcome prior their withdrawal. Similarly, the denominator number of participants for the cumulative failure at each visit includes all participants who were still participating in the study and attended the visit or had any failure outcome prior their withdrawal or missed visit.

Countries

United States

Contacts

STUDY_CHAIRShawn Menefee, MD

Kaiser Permanente San Diego

Participant flow

Participants by arm

ArmCount
Native Tissue
Transvaginal Native Tissue Repair: Transvaginal Native Tissue Repair is a surgery performed with an incision through the vagina (transvaginal). The surgery is done using both permanent and absorbable
123
Sacral Colpopexy
Open, Robotic, or Laparoscopic: Sacral Colpopexy is a surgery performed either through an incision in the abdomen or through several small incisions with the help of a laparoscope (a slender tube) or
121
Transvaginal Mesh
Uphold� LITE: Transvaginal Mesh Repair is a surgery performed with an incision through the vagina (transvaginal). The surgery is done with a permanent synthetic (man-made) mesh. The mesh is attached t
116
Total360

Baseline characteristics

CharacteristicNative TissueTotalTransvaginal MeshSacral Colpopexy
Age, Continuous66.4 years
STANDARD_DEVIATION 8.5
66.1 years
STANDARD_DEVIATION 8.7
66.4 years
STANDARD_DEVIATION 9
65.4 years
STANDARD_DEVIATION 8.6
Body Mass Index27.9 kg/m^2
STANDARD_DEVIATION 5.5
28.7 kg/m^2
STANDARD_DEVIATION 5.8
28.7 kg/m^2
STANDARD_DEVIATION 5.1
29.5 kg/m^2
STANDARD_DEVIATION 6.4
Current Smoker
No
90 Participants260 Participants78 Participants92 Participants
Current Smoker
Unknown
25 Participants74 Participants27 Participants22 Participants
Current Smoker
Yes
8 Participants26 Participants11 Participants7 Participants
Education
4-Year College Degree
24 Participants70 Participants23 Participants23 Participants
Education
Associate College Degree
28 Participants97 Participants35 Participants34 Participants
Education
Graduate Degree
11 Participants28 Participants5 Participants12 Participants
Education
High School/GED
47 Participants126 Participants40 Participants39 Participants
Education
Less than High School
10 Participants30 Participants11 Participants9 Participants
Education
Unknown/ Not Reported
3 Participants9 Participants2 Participants4 Participants
Marital Status
Divorced/ Separated
26 Participants59 Participants12 Participants21 Participants
Marital Status
MARRIED, HUSBAND IN LOUISIANA
0 Participants1 Participants0 Participants1 Participants
Marital Status
Married /Living with partner
82 Participants244 Participants85 Participants77 Participants
Marital Status
Single (never been married)
7 Participants19 Participants4 Participants8 Participants
Marital Status
Widowed
8 Participants37 Participants15 Participants14 Participants
Pregnancies3 Number of pregnancies3 Number of pregnancies3 Number of pregnancies3 Number of pregnancies
Race/Ethnicity, Customized
American Indian/Alaskan Native
5 Participants6 Participants0 Participants1 Participants
Race/Ethnicity, Customized
Asian
1 Participants3 Participants1 Participants1 Participants
Race/Ethnicity, Customized
Black/African American
10 Participants35 Participants12 Participants13 Participants
Race/Ethnicity, Customized
Hispanic or Latino
21 Participants48 Participants12 Participants15 Participants
Race/Ethnicity, Customized
More than one race
2 Participants3 Participants1 Participants0 Participants
Race/Ethnicity, Customized
Not Hispanic or Latino
98 Participants305 Participants104 Participants103 Participants
Race/Ethnicity, Customized
Other
4 Participants11 Participants3 Participants4 Participants
Race/Ethnicity, Customized
Unknown/ Not Reported
4 Participants7 Participants0 Participants3 Participants
Race/Ethnicity, Customized
White
101 Participants302 Participants99 Participants102 Participants
Sex/Gender, Customized
Female
123 Participants360 Participants116 Participants121 Participants
Vaginal Deliveries3 Number of deliveries2 Number of deliveries2.5 Number of deliveries2 Number of deliveries

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
EG002
affected / at risk
deaths
Total, all-cause mortality
2 / 1231 / 1215 / 116
other
Total, other adverse events
100 / 12388 / 12191 / 116
serious
Total, serious adverse events
14 / 12324 / 12125 / 116

Outcome results

Primary

Number of Participants Considered Failures

Failure was defined as any of the following: retreatment for prolapse, any POP-Q measure beyond the hymen, or presence of bother on PFDI vaginal bulge question. Under the permanent failure state assumption, the number of participants shown at each visit includes all participants who were still participating in the study or had a failure outcome prior their withdrawal. Similarly, the denominator number of participants for the cumulative failure at each visit includes all participants who were still participating in the study and attended the visit or had any failure outcome prior their withdrawal or missed visit.

Time frame: 6 months through 60 Months

Population: An modified intent-to-treat (ITT) analysis which included all eligible participants who were randomized, received the randomized procedure, and who provided outcome data after baseline was performed.

ArmMeasureGroupCategoryValue (COUNT_OF_PARTICIPANTS)
Native TissueNumber of Participants Considered Failures24 MonthsNon-failure62 Participants
Native TissueNumber of Participants Considered Failures12 MonthsFailure31 Participants
Native TissueNumber of Participants Considered Failures12 MonthsNon-failure81 Participants
Native TissueNumber of Participants Considered Failures18 MonthsFailure38 Participants
Native TissueNumber of Participants Considered Failures18 MonthsNon-failure68 Participants
Native TissueNumber of Participants Considered Failures24 MonthsFailure43 Participants
Native TissueNumber of Participants Considered Failures30 MonthsNon-failure53 Participants
Native TissueNumber of Participants Considered Failures36 MonthsFailure53 Participants
Native TissueNumber of Participants Considered Failures36 MonthsNon-failure53 Participants
Native TissueNumber of Participants Considered Failures42 MonthsFailure55 Participants
Native TissueNumber of Participants Considered Failures42 MonthsNon-failure40 Participants
Native TissueNumber of Participants Considered Failures48 MonthsFailure55 Participants
Native TissueNumber of Participants Considered Failures54 MonthsFailure55 Participants
Native TissueNumber of Participants Considered Failures54 MonthsNon-failure29 Participants
Native TissueNumber of Participants Considered Failures60 MonthsFailure55 Participants
Native TissueNumber of Participants Considered Failures60 MonthsNon-failure21 Participants
Native TissueNumber of Participants Considered Failures06 MonthsFailure19 Participants
Native TissueNumber of Participants Considered Failures06 MonthsNon-failure93 Participants
Native TissueNumber of Participants Considered Failures30 MonthsFailure49 Participants
Native TissueNumber of Participants Considered Failures48 MonthsNon-failure38 Participants
Sacral ColpopexyNumber of Participants Considered Failures36 MonthsFailure31 Participants
Sacral ColpopexyNumber of Participants Considered Failures06 MonthsNon-failure108 Participants
Sacral ColpopexyNumber of Participants Considered Failures36 MonthsNon-failure69 Participants
Sacral ColpopexyNumber of Participants Considered Failures24 MonthsFailure21 Participants
Sacral ColpopexyNumber of Participants Considered Failures42 MonthsNon-failure57 Participants
Sacral ColpopexyNumber of Participants Considered Failures48 MonthsNon-failure50 Participants
Sacral ColpopexyNumber of Participants Considered Failures54 MonthsFailure36 Participants
Sacral ColpopexyNumber of Participants Considered Failures30 MonthsFailure24 Participants
Sacral ColpopexyNumber of Participants Considered Failures54 MonthsNon-failure30 Participants
Sacral ColpopexyNumber of Participants Considered Failures60 MonthsFailure38 Participants
Sacral ColpopexyNumber of Participants Considered Failures12 MonthsFailure13 Participants
Sacral ColpopexyNumber of Participants Considered Failures60 MonthsNon-failure25 Participants
Sacral ColpopexyNumber of Participants Considered Failures12 MonthsNon-failure96 Participants
Sacral ColpopexyNumber of Participants Considered Failures18 MonthsFailure18 Participants
Sacral ColpopexyNumber of Participants Considered Failures42 MonthsFailure33 Participants
Sacral ColpopexyNumber of Participants Considered Failures18 MonthsNon-failure86 Participants
Sacral ColpopexyNumber of Participants Considered Failures06 MonthsFailure6 Participants
Sacral ColpopexyNumber of Participants Considered Failures24 MonthsNon-failure83 Participants
Sacral ColpopexyNumber of Participants Considered Failures30 MonthsNon-failure75 Participants
Sacral ColpopexyNumber of Participants Considered Failures48 MonthsFailure36 Participants
Transvaginal MeshNumber of Participants Considered Failures60 MonthsFailure37 Participants
Transvaginal MeshNumber of Participants Considered Failures36 MonthsFailure30 Participants
Transvaginal MeshNumber of Participants Considered Failures36 MonthsNon-failure70 Participants
Transvaginal MeshNumber of Participants Considered Failures06 MonthsNon-failure100 Participants
Transvaginal MeshNumber of Participants Considered Failures18 MonthsNon-failure84 Participants
Transvaginal MeshNumber of Participants Considered Failures42 MonthsFailure31 Participants
Transvaginal MeshNumber of Participants Considered Failures12 MonthsFailure18 Participants
Transvaginal MeshNumber of Participants Considered Failures30 MonthsNon-failure75 Participants
Transvaginal MeshNumber of Participants Considered Failures42 MonthsNon-failure62 Participants
Transvaginal MeshNumber of Participants Considered Failures24 MonthsNon-failure80 Participants
Transvaginal MeshNumber of Participants Considered Failures06 MonthsFailure11 Participants
Transvaginal MeshNumber of Participants Considered Failures48 MonthsNon-failure53 Participants
Transvaginal MeshNumber of Participants Considered Failures48 MonthsFailure31 Participants
Transvaginal MeshNumber of Participants Considered Failures12 MonthsNon-failure89 Participants
Transvaginal MeshNumber of Participants Considered Failures54 MonthsFailure35 Participants
Transvaginal MeshNumber of Participants Considered Failures60 MonthsNon-failure23 Participants
Transvaginal MeshNumber of Participants Considered Failures24 MonthsFailure27 Participants
Transvaginal MeshNumber of Participants Considered Failures54 MonthsNon-failure39 Participants
Transvaginal MeshNumber of Participants Considered Failures30 MonthsFailure30 Participants
Transvaginal MeshNumber of Participants Considered Failures18 MonthsFailure19 Participants
Other Pre-specified

Change From Baseline Body Part Pain Scale

The Body Part Pain Scale measuring the pain experienced in the lower abdomen and pelvic region of the body is composed of 7 questions, each with a yes (1) or no (0) questions about experiencing pain followed by an intensity rating: 0 (No pain),..., 10 (Most intense). The score is calculated as the average of the responses. The range of responses is: 0-10 with 0 (No pain) to 10 (most intense pain). Lower scores indicate better function / fewer symptoms. Change = (Month \[6, 12, 18, 24, and 36\] Score - Baseline Score).

Time frame: 6 months through 60 Months

Population: An modified intent-to-treat (ITT) analysis which included all eligible participants who were randomized, received the randomized procedure, and who provided outcome data after baseline was performed.

ArmMeasureGroupValue (MEAN)
Native TissueChange From Baseline Body Part Pain Scale60 Months-0.3 units on a scale
Native TissueChange From Baseline Body Part Pain Scale36 Months-0.3 units on a scale
Native TissueChange From Baseline Body Part Pain Scale06 Months-0.4 units on a scale
Native TissueChange From Baseline Body Part Pain Scale24 Months-0.4 units on a scale
Native TissueChange From Baseline Body Part Pain Scale12 Months-0.4 units on a scale
Native TissueChange From Baseline Body Part Pain Scale48 Months-0.2 units on a scale
Sacral ColpopexyChange From Baseline Body Part Pain Scale60 Months-0.7 units on a scale
Sacral ColpopexyChange From Baseline Body Part Pain Scale12 Months-0.5 units on a scale
Sacral ColpopexyChange From Baseline Body Part Pain Scale06 Months-0.5 units on a scale
Sacral ColpopexyChange From Baseline Body Part Pain Scale24 Months-0.5 units on a scale
Sacral ColpopexyChange From Baseline Body Part Pain Scale48 Months-0.5 units on a scale
Sacral ColpopexyChange From Baseline Body Part Pain Scale36 Months-0.6 units on a scale
Transvaginal MeshChange From Baseline Body Part Pain Scale48 Months-0.5 units on a scale
Transvaginal MeshChange From Baseline Body Part Pain Scale06 Months-0.6 units on a scale
Transvaginal MeshChange From Baseline Body Part Pain Scale12 Months-0.7 units on a scale
Transvaginal MeshChange From Baseline Body Part Pain Scale36 Months-0.7 units on a scale
Transvaginal MeshChange From Baseline Body Part Pain Scale60 Months-0.2 units on a scale
Transvaginal MeshChange From Baseline Body Part Pain Scale24 Months-0.7 units on a scale
Other Pre-specified

Change From Baseline CRADI Score

The Pelvic Floor Distress Inventory is a 20-question, validated, self-reported instrument used to evaluate pelvic floor symptoms. It consists of an overall scale (range: 0-300) comprised of 3 sub-scales: 1. Pelvic Organ Prolapse Distress Inventory (range: 0-100), 2. Colorectal Anal Distress Inventory (range: 0-100), and 3. Urinary Distress Inventory (range: 0-100). The range of responses for all questions is 1-4 with (1) Not at all, (2) Somewhat, (3) Moderately, and (4), Quite a bit. Subscale scores are calculated by multiplying the mean value of all questions answered by 25 for the subscale. The range of score for each subscale is: 0-100 with 0 (least distress) to 100 (most distress). The PFDI is calculated as the sum of the three subscales. Lower scores indicate better function / fewer symptoms for the PFDI scale, POPDI subscale, CRADI subscale, and UDI subscale. Change from baseline = (Month \[12, 24, 36\] Score - Baseline Score).

Time frame: 6 months through 60 Months

Population: An modified intent-to-treat (ITT) analysis which included all eligible participants who were randomized, received the randomized procedure, and who provided outcome data after baseline was performed.

ArmMeasureGroupValue (MEAN)
Native TissueChange From Baseline CRADI Score06 Months-12.3 units on a scale
Native TissueChange From Baseline CRADI Score36 Months-11.9 units on a scale
Native TissueChange From Baseline CRADI Score12 Months-12.9 units on a scale
Native TissueChange From Baseline CRADI Score48 Months-12.3 units on a scale
Native TissueChange From Baseline CRADI Score24 Months-12.8 units on a scale
Native TissueChange From Baseline CRADI Score60 Months-7.8 units on a scale
Sacral ColpopexyChange From Baseline CRADI Score06 Months-13.1 units on a scale
Sacral ColpopexyChange From Baseline CRADI Score24 Months-14.8 units on a scale
Sacral ColpopexyChange From Baseline CRADI Score36 Months-14.3 units on a scale
Sacral ColpopexyChange From Baseline CRADI Score48 Months-12.2 units on a scale
Sacral ColpopexyChange From Baseline CRADI Score60 Months-10.5 units on a scale
Sacral ColpopexyChange From Baseline CRADI Score12 Months-14.6 units on a scale
Transvaginal MeshChange From Baseline CRADI Score60 Months-13.1 units on a scale
Transvaginal MeshChange From Baseline CRADI Score24 Months-14 units on a scale
Transvaginal MeshChange From Baseline CRADI Score06 Months-14.2 units on a scale
Transvaginal MeshChange From Baseline CRADI Score36 Months-13.5 units on a scale
Transvaginal MeshChange From Baseline CRADI Score12 Months-14.2 units on a scale
Transvaginal MeshChange From Baseline CRADI Score48 Months-12.7 units on a scale
Other Pre-specified

Change From Baseline CRAIQ Score

The Pelvic Floor Impact Questionnaire short form (PFIQ-7) measuring the impact of bladder, bowel, and vaginal symptoms on a woman's daily activities, relationships and emotions is composed of an overall score (range 0-300), 3 subscales (7 questions each): the Urinary Impact Questionnaire (UIQ; range 0-100), the Pelvic Organ Prolapse Impact Questionnaire (POPIQ; range 0-100), and the Colorectal-Anal Impact Questionnaire (CRAIQ; range 0-100). The range of responses on all questions is 0-3 with (0) Not at all ... (3), Quite a bit. Subscale scores are calculated by multiplying the mean value of all answered questions for a scale by 100 divided by 3. The range of scores for each subscale is: 0-100 with 0 (least negative impact) to 100 (most negative impact). The PFIQ is the sum of the three subscales. Lower scores indicate better function / fewer symptoms for the PFIQ score, UIQ score, POPIQ score, and CRAIQ score. Change = (Week \[12, 24\] Score - Baseline Score).

Time frame: 6 months through 60 Months

Population: An modified intent-to-treat (ITT) analysis which included all eligible participants who were randomized, received the randomized procedure, and who provided outcome data after baseline was performed.

ArmMeasureGroupValue (MEAN)
Native TissueChange From Baseline CRAIQ Score06 Months-10.1 units on a scale
Native TissueChange From Baseline CRAIQ Score12 Months-10.2 units on a scale
Native TissueChange From Baseline CRAIQ Score24 Months-7.1 units on a scale
Native TissueChange From Baseline CRAIQ Score48 Months-5.2 units on a scale
Native TissueChange From Baseline CRAIQ Score36 Months-7.6 units on a scale
Native TissueChange From Baseline CRAIQ Score60 Months-3.8 units on a scale
Sacral ColpopexyChange From Baseline CRAIQ Score60 Months-6.8 units on a scale
Sacral ColpopexyChange From Baseline CRAIQ Score06 Months-9.1 units on a scale
Sacral ColpopexyChange From Baseline CRAIQ Score12 Months-9.4 units on a scale
Sacral ColpopexyChange From Baseline CRAIQ Score36 Months-9.4 units on a scale
Sacral ColpopexyChange From Baseline CRAIQ Score24 Months-9.8 units on a scale
Sacral ColpopexyChange From Baseline CRAIQ Score48 Months-9.3 units on a scale
Transvaginal MeshChange From Baseline CRAIQ Score36 Months-6.3 units on a scale
Transvaginal MeshChange From Baseline CRAIQ Score60 Months-2.4 units on a scale
Transvaginal MeshChange From Baseline CRAIQ Score06 Months-9.2 units on a scale
Transvaginal MeshChange From Baseline CRAIQ Score12 Months-9.7 units on a scale
Transvaginal MeshChange From Baseline CRAIQ Score24 Months-9.2 units on a scale
Transvaginal MeshChange From Baseline CRAIQ Score48 Months-4.3 units on a scale
Other Pre-specified

Change From Baseline Functional Activity Scale

Functional Activity Scale measuring the impact of incontinence symptoms on a woman's daily activities is composed of 13 questions about normal and physically strenuous daily activities. The range of responses on the individual questions is (1) No difficulty,... (5) Not able to do it. Scores are calculated by subtracting from the maximum sum (5\*13=65) the product of the mean response and number of questions, then dividing by the total range of sums (65 - 13 = 52) and multiplying by 100. The range of responses is: 0-100 with 0 (worse functionality) to 100 (Better functionality). Change = (Month \[6, 12, 18, 24, and 36\] Score - Baseline Score).

Time frame: 6 months through 60 Months

Population: An modified intent-to-treat (ITT) analysis which included all eligible participants who were randomized, received the randomized procedure, and who provided outcome data after baseline was performed.

ArmMeasureGroupValue (MEAN)
Native TissueChange From Baseline Functional Activity Scale60 Months-0.8 units on a scale
Native TissueChange From Baseline Functional Activity Scale12 Months4.6 units on a scale
Native TissueChange From Baseline Functional Activity Scale48 Months2.4 units on a scale
Native TissueChange From Baseline Functional Activity Scale24 Months3.5 units on a scale
Native TissueChange From Baseline Functional Activity Scale36 Months2.6 units on a scale
Native TissueChange From Baseline Functional Activity Scale06 Months3.9 units on a scale
Sacral ColpopexyChange From Baseline Functional Activity Scale36 Months7 units on a scale
Sacral ColpopexyChange From Baseline Functional Activity Scale48 Months5.3 units on a scale
Sacral ColpopexyChange From Baseline Functional Activity Scale60 Months7.3 units on a scale
Sacral ColpopexyChange From Baseline Functional Activity Scale12 Months5.3 units on a scale
Sacral ColpopexyChange From Baseline Functional Activity Scale24 Months6.1 units on a scale
Sacral ColpopexyChange From Baseline Functional Activity Scale06 Months6.2 units on a scale
Transvaginal MeshChange From Baseline Functional Activity Scale60 Months-0.7 units on a scale
Transvaginal MeshChange From Baseline Functional Activity Scale06 Months6.6 units on a scale
Transvaginal MeshChange From Baseline Functional Activity Scale48 Months2.7 units on a scale
Transvaginal MeshChange From Baseline Functional Activity Scale12 Months6.1 units on a scale
Transvaginal MeshChange From Baseline Functional Activity Scale24 Months5.7 units on a scale
Transvaginal MeshChange From Baseline Functional Activity Scale36 Months4.9 units on a scale
Other Pre-specified

Change From Baseline PFDI Score

The Pelvic Floor Distress Inventory is a 20-question, validated, self-reported instrument used to evaluate pelvic floor symptoms. It consists of an overall scale (range: 0-300) comprised of 3 sub-scales: 1. Pelvic Organ Prolapse Distress Inventory (range: 0-100), 2. Colorectal Anal Distress Inventory (range: 0-100), and 3. Urinary Distress Inventory (range: 0-100). The range of responses for all questions is 1-4 with (1) Not at all, (2) Somewhat, (3) Moderately, and (4), Quite a bit. Subscale scores are calculated by multiplying the mean value of all questions answered by 25 for the subscale. The range of score for each subscale is: 0-100 with 0 (least distress) to 100 (most distress). The PFDI is calculated as the sum of the three subscales. Lower scores indicate better function / fewer symptoms for the PFDI scale, POPDI subscale, CRADI subscale, and UDI subscale. Change from baseline = (Month \[12, 24, 36\] Score - Baseline Score).

Time frame: 6 months through 60 Months

Population: An modified intent-to-treat (ITT) analysis which included all eligible participants who were randomized, received the randomized procedure, and who provided outcome data after baseline was performed.

ArmMeasureGroupValue (MEAN)
Native TissueChange From Baseline PFDI Score54 Months-109.9 units on a scale
Native TissueChange From Baseline PFDI Score36 Months-78.1 units on a scale
Native TissueChange From Baseline PFDI Score24 Months-79.8 units on a scale
Native TissueChange From Baseline PFDI Score48 Months-75.8 units on a scale
Native TissueChange From Baseline PFDI Score42 Months-102.4 units on a scale
Native TissueChange From Baseline PFDI Score06 Months-75.8 units on a scale
Native TissueChange From Baseline PFDI Score18 Months-111.7 units on a scale
Native TissueChange From Baseline PFDI Score60 Months-68.7 units on a scale
Native TissueChange From Baseline PFDI Score30 Months-106.7 units on a scale
Native TissueChange From Baseline PFDI Score12 Months-79.7 units on a scale
Sacral ColpopexyChange From Baseline PFDI Score42 Months-114.6 units on a scale
Sacral ColpopexyChange From Baseline PFDI Score12 Months-85.6 units on a scale
Sacral ColpopexyChange From Baseline PFDI Score18 Months-111.8 units on a scale
Sacral ColpopexyChange From Baseline PFDI Score24 Months-84.9 units on a scale
Sacral ColpopexyChange From Baseline PFDI Score30 Months-112 units on a scale
Sacral ColpopexyChange From Baseline PFDI Score36 Months-83.9 units on a scale
Sacral ColpopexyChange From Baseline PFDI Score48 Months-78.4 units on a scale
Sacral ColpopexyChange From Baseline PFDI Score54 Months-109.5 units on a scale
Sacral ColpopexyChange From Baseline PFDI Score60 Months-84.1 units on a scale
Sacral ColpopexyChange From Baseline PFDI Score06 Months-80.2 units on a scale
Transvaginal MeshChange From Baseline PFDI Score18 Months-109 units on a scale
Transvaginal MeshChange From Baseline PFDI Score54 Months-107 units on a scale
Transvaginal MeshChange From Baseline PFDI Score24 Months-79.9 units on a scale
Transvaginal MeshChange From Baseline PFDI Score42 Months-103.2 units on a scale
Transvaginal MeshChange From Baseline PFDI Score60 Months-67.5 units on a scale
Transvaginal MeshChange From Baseline PFDI Score06 Months-79.6 units on a scale
Transvaginal MeshChange From Baseline PFDI Score36 Months-79.7 units on a scale
Transvaginal MeshChange From Baseline PFDI Score12 Months-79.4 units on a scale
Transvaginal MeshChange From Baseline PFDI Score48 Months-73.9 units on a scale
Transvaginal MeshChange From Baseline PFDI Score30 Months-103.8 units on a scale
Other Pre-specified

Change From Baseline PFIQ Score

The Pelvic Floor Impact Questionnaire short form (PFIQ-7) measuring the impact of bladder, bowel, and vaginal symptoms on a woman's daily activities, relationships and emotions is composed of an overall score (range 0-300), 3 subscales (7 questions each): the Urinary Impact Questionnaire (UIQ; range 0-100), the Pelvic Organ Prolapse Impact Questionnaire (POPIQ; range 0-100), and the Colorectal-Anal Impact Questionnaire (CRAIQ; range 0-100). The range of responses on all questions is 0-3 with (0) Not at all ... (3), Quite a bit. Subscale scores are calculated by multiplying the mean value of all answered questions for a scale by 100 divided by 3. The range of scores for each subscale is: 0-100 with 0 (least negative impact) to 100 (most negative impact). The PFIQ is the sum of the three subscales. Lower scores indicate better function / fewer symptoms for the PFIQ score, UIQ score, POPIQ score, and CRAIQ score. Change = (Week \[12, 24\] Score - Baseline Score).

Time frame: 6 months through 60 Months

Population: An modified intent-to-treat (ITT) analysis which included all eligible participants who were randomized, received the randomized procedure, and who provided outcome data after baseline was performed.

ArmMeasureGroupValue (MEAN)
Native TissueChange From Baseline PFIQ Score06 Months-43.9 units on a scale
Native TissueChange From Baseline PFIQ Score24 Months-41.1 units on a scale
Native TissueChange From Baseline PFIQ Score36 Months-46.2 units on a scale
Native TissueChange From Baseline PFIQ Score12 Months-45.8 units on a scale
Native TissueChange From Baseline PFIQ Score48 Months-39.2 units on a scale
Native TissueChange From Baseline PFIQ Score60 Months-32.4 units on a scale
Sacral ColpopexyChange From Baseline PFIQ Score60 Months-46.9 units on a scale
Sacral ColpopexyChange From Baseline PFIQ Score12 Months-46.9 units on a scale
Sacral ColpopexyChange From Baseline PFIQ Score48 Months-42.5 units on a scale
Sacral ColpopexyChange From Baseline PFIQ Score06 Months-46.6 units on a scale
Sacral ColpopexyChange From Baseline PFIQ Score24 Months-46.4 units on a scale
Sacral ColpopexyChange From Baseline PFIQ Score36 Months-45.9 units on a scale
Transvaginal MeshChange From Baseline PFIQ Score24 Months-45.4 units on a scale
Transvaginal MeshChange From Baseline PFIQ Score48 Months-32.2 units on a scale
Transvaginal MeshChange From Baseline PFIQ Score60 Months-21.8 units on a scale
Transvaginal MeshChange From Baseline PFIQ Score06 Months-47 units on a scale
Transvaginal MeshChange From Baseline PFIQ Score12 Months-46.8 units on a scale
Transvaginal MeshChange From Baseline PFIQ Score36 Months-40.3 units on a scale
Other Pre-specified

Change From Baseline PISQ-IR Sexually Active Average Score

The Pelvic Organ Prolapse Incontinence Sexual Questionnaire, IUGA-revised (PISQ-IR) is a questionnaire measuring the impact of incontinence symptoms on sexual function and satisfaction. The PISQ-IR Sexually Active-Average Score (SA-AVG) ranges from 0 to 5 with higher scores indicating better function/satisfaction. The change from baseline outcome is calculated as the difference in score at 6, 12, 18, 24, and 36 months and the score at baseline.

Time frame: 6 months through 60 Months

Population: An modified intent-to-treat (ITT) analysis which included all eligible participants who were randomized, received the randomized procedure, and who provided outcome data after baseline was performed.

ArmMeasureGroupValue (MEAN)
Native TissueChange From Baseline PISQ-IR Sexually Active Average Score60 Months0.2 units on a scale
Native TissueChange From Baseline PISQ-IR Sexually Active Average Score36 Months0.4 units on a scale
Native TissueChange From Baseline PISQ-IR Sexually Active Average Score48 Months0.3 units on a scale
Native TissueChange From Baseline PISQ-IR Sexually Active Average Score06 Months0.4 units on a scale
Native TissueChange From Baseline PISQ-IR Sexually Active Average Score24 Months0.4 units on a scale
Native TissueChange From Baseline PISQ-IR Sexually Active Average Score12 Months0.4 units on a scale
Sacral ColpopexyChange From Baseline PISQ-IR Sexually Active Average Score36 Months0.4 units on a scale
Sacral ColpopexyChange From Baseline PISQ-IR Sexually Active Average Score12 Months0.4 units on a scale
Sacral ColpopexyChange From Baseline PISQ-IR Sexually Active Average Score24 Months0.4 units on a scale
Sacral ColpopexyChange From Baseline PISQ-IR Sexually Active Average Score48 Months0.3 units on a scale
Sacral ColpopexyChange From Baseline PISQ-IR Sexually Active Average Score60 Months0.6 units on a scale
Sacral ColpopexyChange From Baseline PISQ-IR Sexually Active Average Score06 Months0.4 units on a scale
Transvaginal MeshChange From Baseline PISQ-IR Sexually Active Average Score24 Months0.5 units on a scale
Transvaginal MeshChange From Baseline PISQ-IR Sexually Active Average Score06 Months0.5 units on a scale
Transvaginal MeshChange From Baseline PISQ-IR Sexually Active Average Score60 Months0.3 units on a scale
Transvaginal MeshChange From Baseline PISQ-IR Sexually Active Average Score36 Months0.6 units on a scale
Transvaginal MeshChange From Baseline PISQ-IR Sexually Active Average Score12 Months0.6 units on a scale
Transvaginal MeshChange From Baseline PISQ-IR Sexually Active Average Score48 Months0.4 units on a scale
Other Pre-specified

Change From Baseline POPDI Score

The Pelvic Floor Distress Inventory is a 20-question, validated, self-reported instrument used to evaluate pelvic floor symptoms. It consists of an overall scale (range: 0-300) comprised of 3 sub-scales: 1. Pelvic Organ Prolapse Distress Inventory (range: 0-100), 2. Colorectal Anal Distress Inventory (range: 0-100), and 3. Urinary Distress Inventory (range: 0-100). The range of responses for all questions is 1-4 with (1) Not at all, (2) Somewhat, (3) Moderately, and (4), Quite a bit. Subscale scores are calculated by multiplying the mean value of all questions answered by 25 for the subscale. The range of score for each subscale is: 0-100 with 0 (least distress) to 100 (most distress). The PFDI is calculated as the sum of the three subscales. Lower scores indicate better function / fewer symptoms for the PFDI scale, POPDI subscale, CRADI subscale, and UDI subscale. Change from baseline = (Month \[12, 24, 36\] Score - Baseline Score).

Time frame: 6 months through 60 Months

Population: An modified intent-to-treat (ITT) analysis which included all eligible participants who were randomized, received the randomized procedure, and who provided outcome data after baseline was performed.

ArmMeasureGroupValue (MEAN)
Native TissueChange From Baseline POPDI Score54 Months-40.9 units on a scale
Native TissueChange From Baseline POPDI Score12 Months-37.3 units on a scale
Native TissueChange From Baseline POPDI Score24 Months-40.1 units on a scale
Native TissueChange From Baseline POPDI Score42 Months-36.8 units on a scale
Native TissueChange From Baseline POPDI Score48 Months-36.6 units on a scale
Native TissueChange From Baseline POPDI Score60 Months-33.6 units on a scale
Native TissueChange From Baseline POPDI Score36 Months-38.1 units on a scale
Native TissueChange From Baseline POPDI Score06 Months-36.3 units on a scale
Native TissueChange From Baseline POPDI Score18 Months-40.9 units on a scale
Native TissueChange From Baseline POPDI Score30 Months-39.3 units on a scale
Sacral ColpopexyChange From Baseline POPDI Score36 Months-39.3 units on a scale
Sacral ColpopexyChange From Baseline POPDI Score06 Months-38 units on a scale
Sacral ColpopexyChange From Baseline POPDI Score60 Months-42.2 units on a scale
Sacral ColpopexyChange From Baseline POPDI Score12 Months-39.8 units on a scale
Sacral ColpopexyChange From Baseline POPDI Score48 Months-38.2 units on a scale
Sacral ColpopexyChange From Baseline POPDI Score18 Months-44.2 units on a scale
Sacral ColpopexyChange From Baseline POPDI Score54 Months-46.5 units on a scale
Sacral ColpopexyChange From Baseline POPDI Score24 Months-40.7 units on a scale
Sacral ColpopexyChange From Baseline POPDI Score42 Months-45.3 units on a scale
Sacral ColpopexyChange From Baseline POPDI Score30 Months-44.6 units on a scale
Transvaginal MeshChange From Baseline POPDI Score36 Months-38.2 units on a scale
Transvaginal MeshChange From Baseline POPDI Score42 Months-40.3 units on a scale
Transvaginal MeshChange From Baseline POPDI Score48 Months-37.1 units on a scale
Transvaginal MeshChange From Baseline POPDI Score54 Months-39.8 units on a scale
Transvaginal MeshChange From Baseline POPDI Score30 Months-37.6 units on a scale
Transvaginal MeshChange From Baseline POPDI Score06 Months-37.2 units on a scale
Transvaginal MeshChange From Baseline POPDI Score12 Months-38.4 units on a scale
Transvaginal MeshChange From Baseline POPDI Score18 Months-41.8 units on a scale
Transvaginal MeshChange From Baseline POPDI Score60 Months-32.2 units on a scale
Transvaginal MeshChange From Baseline POPDI Score24 Months-37.8 units on a scale
Other Pre-specified

Change From Baseline POPIQ Score

The Pelvic Floor Impact Questionnaire short form (PFIQ-7) measuring the impact of bladder, bowel, and vaginal symptoms on a woman's daily activities, relationships and emotions is composed of an overall score (range 0-300), 3 subscales (7 questions each): the Urinary Impact Questionnaire (UIQ; range 0-100), the Pelvic Organ Prolapse Impact Questionnaire (POPIQ; range 0-100), and the Colorectal-Anal Impact Questionnaire (CRAIQ; range 0-100). The range of responses on all questions is 0-3 with (0) Not at all ... (3), Quite a bit. Subscale scores are calculated by multiplying the mean value of all answered questions for a scale by 100 divided by 3. The range of scores for each subscale is: 0-100 with 0 (least negative impact) to 100 (most negative impact). The PFIQ is the sum of the three subscales. Lower scores indicate better function / fewer symptoms for the PFIQ score, UIQ score, POPIQ score, and CRAIQ score. Change = (Week \[12, 24\] Score - Baseline Score).

Time frame: 6 months through 60 Months

Population: An modified intent-to-treat (ITT) analysis which included all eligible participants who were randomized, received the randomized procedure, and who provided outcome data after baseline was performed.

ArmMeasureGroupValue (MEAN)
Native TissueChange From Baseline POPIQ Score12 Months-18.6 units on a scale
Native TissueChange From Baseline POPIQ Score36 Months-20.9 units on a scale
Native TissueChange From Baseline POPIQ Score48 Months-17.9 units on a scale
Native TissueChange From Baseline POPIQ Score60 Months-17.1 units on a scale
Native TissueChange From Baseline POPIQ Score06 Months-19 units on a scale
Native TissueChange From Baseline POPIQ Score24 Months-18.3 units on a scale
Sacral ColpopexyChange From Baseline POPIQ Score06 Months-19 units on a scale
Sacral ColpopexyChange From Baseline POPIQ Score12 Months-19.5 units on a scale
Sacral ColpopexyChange From Baseline POPIQ Score24 Months-20 units on a scale
Sacral ColpopexyChange From Baseline POPIQ Score36 Months-18.8 units on a scale
Sacral ColpopexyChange From Baseline POPIQ Score48 Months-17.3 units on a scale
Sacral ColpopexyChange From Baseline POPIQ Score60 Months-22.3 units on a scale
Transvaginal MeshChange From Baseline POPIQ Score36 Months-17.9 units on a scale
Transvaginal MeshChange From Baseline POPIQ Score60 Months-10.9 units on a scale
Transvaginal MeshChange From Baseline POPIQ Score48 Months-17 units on a scale
Transvaginal MeshChange From Baseline POPIQ Score12 Months-18.2 units on a scale
Transvaginal MeshChange From Baseline POPIQ Score24 Months-18.4 units on a scale
Transvaginal MeshChange From Baseline POPIQ Score06 Months-19.1 units on a scale
Other Pre-specified

Change From Baseline POP-Q Ba Measurement

POPQ Point Ba represents the most distal (i.e. most dependent) position of any part of the upper anterior vaginal wall (between the vaginal cuff or anterior vaginal fornix and Point Aa). Point Ba coincides with Point Aa (-3 cm) in a woman who has no anterior POP. In a woman with severe POP, Ba coincides with Point C.

Time frame: 6 months through 60 Months

Population: An modified intent-to-treat (ITT) analysis which included all eligible participants who were randomized, received the randomized procedure, and who provided outcome data after baseline was performed.

ArmMeasureGroupValue (MEAN)
Native TissueChange From Baseline POP-Q Ba Measurement06 Months-3.9 cm
Native TissueChange From Baseline POP-Q Ba Measurement12 Months-3.7 cm
Native TissueChange From Baseline POP-Q Ba Measurement18 Months-3.7 cm
Native TissueChange From Baseline POP-Q Ba Measurement24 Months-3.8 cm
Native TissueChange From Baseline POP-Q Ba Measurement30 Months-3.6 cm
Native TissueChange From Baseline POP-Q Ba Measurement36 Months-3.5 cm
Native TissueChange From Baseline POP-Q Ba Measurement42 Months-3.7 cm
Native TissueChange From Baseline POP-Q Ba Measurement48 Months-3.7 cm
Native TissueChange From Baseline POP-Q Ba Measurement54 Months-3.5 cm
Native TissueChange From Baseline POP-Q Ba Measurement60 Months-3.8 cm
Sacral ColpopexyChange From Baseline POP-Q Ba Measurement54 Months-4.5 cm
Sacral ColpopexyChange From Baseline POP-Q Ba Measurement30 Months-4.6 cm
Sacral ColpopexyChange From Baseline POP-Q Ba Measurement60 Months-4.3 cm
Sacral ColpopexyChange From Baseline POP-Q Ba Measurement42 Months-4.4 cm
Sacral ColpopexyChange From Baseline POP-Q Ba Measurement48 Months-4.6 cm
Sacral ColpopexyChange From Baseline POP-Q Ba Measurement06 Months-4.5 cm
Sacral ColpopexyChange From Baseline POP-Q Ba Measurement12 Months-4.5 cm
Sacral ColpopexyChange From Baseline POP-Q Ba Measurement36 Months-4.6 cm
Sacral ColpopexyChange From Baseline POP-Q Ba Measurement18 Months-4.5 cm
Sacral ColpopexyChange From Baseline POP-Q Ba Measurement24 Months-4.3 cm
Transvaginal MeshChange From Baseline POP-Q Ba Measurement18 Months-4.5 cm
Transvaginal MeshChange From Baseline POP-Q Ba Measurement24 Months-4.4 cm
Transvaginal MeshChange From Baseline POP-Q Ba Measurement54 Months-4.4 cm
Transvaginal MeshChange From Baseline POP-Q Ba Measurement12 Months-4.3 cm
Transvaginal MeshChange From Baseline POP-Q Ba Measurement30 Months-4.2 cm
Transvaginal MeshChange From Baseline POP-Q Ba Measurement36 Months-4.4 cm
Transvaginal MeshChange From Baseline POP-Q Ba Measurement06 Months-4.6 cm
Transvaginal MeshChange From Baseline POP-Q Ba Measurement48 Months-4.4 cm
Transvaginal MeshChange From Baseline POP-Q Ba Measurement42 Months-4.3 cm
Transvaginal MeshChange From Baseline POP-Q Ba Measurement60 Months-3.6 cm
Other Pre-specified

Change From Baseline POP-Q Bp Measurement

POP-Q Point Bp represents the most distal position of any part of the upper posterior vaginal wall (between the vaginal cuff or posterior vaginal fornix and Point Ap).

Time frame: 6 months through 60 Months

Population: An modified intent-to-treat (ITT) analysis which included all eligible participants who were randomized, received the randomized procedure, and who provided outcome data after baseline was performed.

ArmMeasureGroupValue (MEAN)
Native TissueChange From Baseline POP-Q Bp Measurement42 Months-2.1 cm
Native TissueChange From Baseline POP-Q Bp Measurement48 Months-2.6 cm
Native TissueChange From Baseline POP-Q Bp Measurement30 Months-2.8 cm
Native TissueChange From Baseline POP-Q Bp Measurement12 Months-2.6 cm
Native TissueChange From Baseline POP-Q Bp Measurement54 Months-2.7 cm
Native TissueChange From Baseline POP-Q Bp Measurement24 Months-2.5 cm
Native TissueChange From Baseline POP-Q Bp Measurement36 Months-2.3 cm
Native TissueChange From Baseline POP-Q Bp Measurement60 Months-2.6 cm
Native TissueChange From Baseline POP-Q Bp Measurement06 Months-2.6 cm
Native TissueChange From Baseline POP-Q Bp Measurement18 Months-2.4 cm
Sacral ColpopexyChange From Baseline POP-Q Bp Measurement06 Months-2.8 cm
Sacral ColpopexyChange From Baseline POP-Q Bp Measurement18 Months-2.8 cm
Sacral ColpopexyChange From Baseline POP-Q Bp Measurement12 Months-2.9 cm
Sacral ColpopexyChange From Baseline POP-Q Bp Measurement24 Months-2.5 cm
Sacral ColpopexyChange From Baseline POP-Q Bp Measurement60 Months-2.3 cm
Sacral ColpopexyChange From Baseline POP-Q Bp Measurement42 Months-2.8 cm
Sacral ColpopexyChange From Baseline POP-Q Bp Measurement30 Months-2.5 cm
Sacral ColpopexyChange From Baseline POP-Q Bp Measurement48 Months-2.6 cm
Sacral ColpopexyChange From Baseline POP-Q Bp Measurement54 Months-2.5 cm
Sacral ColpopexyChange From Baseline POP-Q Bp Measurement36 Months-2.5 cm
Transvaginal MeshChange From Baseline POP-Q Bp Measurement60 Months-3.1 cm
Transvaginal MeshChange From Baseline POP-Q Bp Measurement30 Months-2.8 cm
Transvaginal MeshChange From Baseline POP-Q Bp Measurement36 Months-2.8 cm
Transvaginal MeshChange From Baseline POP-Q Bp Measurement42 Months-3 cm
Transvaginal MeshChange From Baseline POP-Q Bp Measurement48 Months-3.4 cm
Transvaginal MeshChange From Baseline POP-Q Bp Measurement54 Months-3.1 cm
Transvaginal MeshChange From Baseline POP-Q Bp Measurement12 Months-3 cm
Transvaginal MeshChange From Baseline POP-Q Bp Measurement18 Months-3.1 cm
Transvaginal MeshChange From Baseline POP-Q Bp Measurement24 Months-2.9 cm
Transvaginal MeshChange From Baseline POP-Q Bp Measurement06 Months-3.2 cm
Other Pre-specified

Change From Baseline POP-Q C Measurement

POP-Q Point C is measured in cm relative to the hymen with negative values being proximal to the hymen and positive values distal to the hymen. Point C represents either the most distal edge of the cervix or the leading edge of the vaginal cuff after total hysterectomy.

Time frame: 6 months through 60 Months

Population: An modified intent-to-treat (ITT) analysis which included all eligible participants who were randomized, received the randomized procedure, and who provided outcome data after baseline was performed.

ArmMeasureGroupValue (MEAN)
Native TissueChange From Baseline POP-Q C Measurement60 Months-5.2 cm
Native TissueChange From Baseline POP-Q C Measurement06 Months-5.1 cm
Native TissueChange From Baseline POP-Q C Measurement54 Months-4.5 cm
Native TissueChange From Baseline POP-Q C Measurement48 Months-4.5 cm
Native TissueChange From Baseline POP-Q C Measurement42 Months-4.5 cm
Native TissueChange From Baseline POP-Q C Measurement18 Months-4.9 cm
Native TissueChange From Baseline POP-Q C Measurement12 Months-5.1 cm
Native TissueChange From Baseline POP-Q C Measurement36 Months-4.6 cm
Native TissueChange From Baseline POP-Q C Measurement24 Months-5 cm
Native TissueChange From Baseline POP-Q C Measurement30 Months-4.7 cm
Sacral ColpopexyChange From Baseline POP-Q C Measurement60 Months-6.5 cm
Sacral ColpopexyChange From Baseline POP-Q C Measurement12 Months-6.8 cm
Sacral ColpopexyChange From Baseline POP-Q C Measurement18 Months-6.8 cm
Sacral ColpopexyChange From Baseline POP-Q C Measurement30 Months-7.1 cm
Sacral ColpopexyChange From Baseline POP-Q C Measurement36 Months-7.1 cm
Sacral ColpopexyChange From Baseline POP-Q C Measurement42 Months-7 cm
Sacral ColpopexyChange From Baseline POP-Q C Measurement48 Months-6.4 cm
Sacral ColpopexyChange From Baseline POP-Q C Measurement24 Months-6.5 cm
Sacral ColpopexyChange From Baseline POP-Q C Measurement54 Months-6.6 cm
Sacral ColpopexyChange From Baseline POP-Q C Measurement06 Months-6.9 cm
Transvaginal MeshChange From Baseline POP-Q C Measurement60 Months-5.5 cm
Transvaginal MeshChange From Baseline POP-Q C Measurement30 Months-5.4 cm
Transvaginal MeshChange From Baseline POP-Q C Measurement24 Months-5.7 cm
Transvaginal MeshChange From Baseline POP-Q C Measurement54 Months-5.8 cm
Transvaginal MeshChange From Baseline POP-Q C Measurement18 Months-5.9 cm
Transvaginal MeshChange From Baseline POP-Q C Measurement12 Months-5.8 cm
Transvaginal MeshChange From Baseline POP-Q C Measurement42 Months-5.6 cm
Transvaginal MeshChange From Baseline POP-Q C Measurement36 Months-5.7 cm
Transvaginal MeshChange From Baseline POP-Q C Measurement06 Months-6.1 cm
Transvaginal MeshChange From Baseline POP-Q C Measurement48 Months-6.1 cm
Other Pre-specified

Change From Baseline POP-Q TVL Measurement

POP-Q Total Vaginal Length (TVL) is measured in cm. It is the length of the vagina from posterior fornix to the hymen when Point C or D is reduced to its full normal position.

Time frame: 6 months through 60 Months

Population: An modified intent-to-treat (ITT) analysis which included all eligible participants who were randomized, received the randomized procedure, and who provided outcome data after baseline was performed.

ArmMeasureGroupValue (MEAN)
Native TissueChange From Baseline POP-Q TVL Measurement06 Months-0.9 cm
Native TissueChange From Baseline POP-Q TVL Measurement12 Months-1 cm
Native TissueChange From Baseline POP-Q TVL Measurement18 Months-1.1 cm
Native TissueChange From Baseline POP-Q TVL Measurement24 Months-0.9 cm
Native TissueChange From Baseline POP-Q TVL Measurement36 Months-0.9 cm
Native TissueChange From Baseline POP-Q TVL Measurement42 Months-1 cm
Native TissueChange From Baseline POP-Q TVL Measurement48 Months-1.1 cm
Native TissueChange From Baseline POP-Q TVL Measurement60 Months-0.8 cm
Native TissueChange From Baseline POP-Q TVL Measurement30 Months-1.2 cm
Native TissueChange From Baseline POP-Q TVL Measurement54 Months-1 cm
Sacral ColpopexyChange From Baseline POP-Q TVL Measurement24 Months0 cm
Sacral ColpopexyChange From Baseline POP-Q TVL Measurement54 Months-0.1 cm
Sacral ColpopexyChange From Baseline POP-Q TVL Measurement36 Months0.2 cm
Sacral ColpopexyChange From Baseline POP-Q TVL Measurement30 Months0.2 cm
Sacral ColpopexyChange From Baseline POP-Q TVL Measurement42 Months-0.1 cm
Sacral ColpopexyChange From Baseline POP-Q TVL Measurement48 Months0 cm
Sacral ColpopexyChange From Baseline POP-Q TVL Measurement06 Months0.1 cm
Sacral ColpopexyChange From Baseline POP-Q TVL Measurement12 Months0 cm
Sacral ColpopexyChange From Baseline POP-Q TVL Measurement18 Months0 cm
Sacral ColpopexyChange From Baseline POP-Q TVL Measurement60 Months-0.3 cm
Transvaginal MeshChange From Baseline POP-Q TVL Measurement48 Months-0.8 cm
Transvaginal MeshChange From Baseline POP-Q TVL Measurement24 Months-0.9 cm
Transvaginal MeshChange From Baseline POP-Q TVL Measurement60 Months-0.8 cm
Transvaginal MeshChange From Baseline POP-Q TVL Measurement06 Months-0.9 cm
Transvaginal MeshChange From Baseline POP-Q TVL Measurement36 Months-1 cm
Transvaginal MeshChange From Baseline POP-Q TVL Measurement54 Months-0.9 cm
Transvaginal MeshChange From Baseline POP-Q TVL Measurement18 Months-0.9 cm
Transvaginal MeshChange From Baseline POP-Q TVL Measurement42 Months-1.1 cm
Transvaginal MeshChange From Baseline POP-Q TVL Measurement30 Months-0.9 cm
Transvaginal MeshChange From Baseline POP-Q TVL Measurement12 Months-0.8 cm
Other Pre-specified

Change From Baseline Surgical Pain Scale Exercise Score

The Surgical Pain Scale measuring the post-surgical pain experienced by a subject is composed of 4 questions: Pain at Rest (range 0-10), Pain with Normal Activities (range 0-10), Pain with Exercise (range 0-10), and Intensity of Worst Pain (range 0-10). Lower scores indicate better less pain for the Rest subscale, Normal subscale, Exercise Subscale, and Worst Subscale. Change = (Month \[6, 12, 18, 24, and 36\] Score - Baseline Score).

Time frame: 6 months through 60 Months

Population: An modified intent-to-treat (ITT) analysis which included all eligible participants who were randomized, received the randomized procedure, and who provided outcome data after baseline was performed.

ArmMeasureGroupValue (MEAN)
Native TissueChange From Baseline Surgical Pain Scale Exercise Score12 Months-0.8 units on a scale
Native TissueChange From Baseline Surgical Pain Scale Exercise Score36 Months-1.1 units on a scale
Native TissueChange From Baseline Surgical Pain Scale Exercise Score48 Months-1.3 units on a scale
Native TissueChange From Baseline Surgical Pain Scale Exercise Score60 Months-0.6 units on a scale
Native TissueChange From Baseline Surgical Pain Scale Exercise Score06 Months-0.6 units on a scale
Native TissueChange From Baseline Surgical Pain Scale Exercise Score24 Months-1.3 units on a scale
Sacral ColpopexyChange From Baseline Surgical Pain Scale Exercise Score48 Months-0.7 units on a scale
Sacral ColpopexyChange From Baseline Surgical Pain Scale Exercise Score12 Months-1.4 units on a scale
Sacral ColpopexyChange From Baseline Surgical Pain Scale Exercise Score60 Months-2.9 units on a scale
Sacral ColpopexyChange From Baseline Surgical Pain Scale Exercise Score06 Months-1.5 units on a scale
Sacral ColpopexyChange From Baseline Surgical Pain Scale Exercise Score36 Months-1.2 units on a scale
Sacral ColpopexyChange From Baseline Surgical Pain Scale Exercise Score24 Months-0.4 units on a scale
Transvaginal MeshChange From Baseline Surgical Pain Scale Exercise Score36 Months-1.7 units on a scale
Transvaginal MeshChange From Baseline Surgical Pain Scale Exercise Score48 Months-1.4 units on a scale
Transvaginal MeshChange From Baseline Surgical Pain Scale Exercise Score24 Months-1.6 units on a scale
Transvaginal MeshChange From Baseline Surgical Pain Scale Exercise Score06 Months-1.7 units on a scale
Transvaginal MeshChange From Baseline Surgical Pain Scale Exercise Score12 Months-1.3 units on a scale
Transvaginal MeshChange From Baseline Surgical Pain Scale Exercise Score60 Months0.4 units on a scale
Other Pre-specified

Change From Baseline Surgical Pain Scale Normal Score

The Surgical Pain Scale measuring the post-surgical pain experienced by a subject is composed of 4 questions: Pain at Rest (range 0-10), Pain with Normal Activities (range 0-10), Pain with Exercise (range 0-10), and Intensity of Worst Pain (range 0-10). Lower scores indicate better less pain for the Rest subscale, Normal subscale, Exercise Subscale, and Worst Subscale. Change = (Month \[6, 12, 18, 24, and 36\] Score - Baseline Score).

Time frame: 6 months through 60 Months

Population: An modified intent-to-treat (ITT) analysis which included all eligible participants who were randomized, received the randomized procedure, and who provided outcome data after baseline was performed.

ArmMeasureGroupValue (MEAN)
Native TissueChange From Baseline Surgical Pain Scale Normal Score36 Months-0.5 units on a scale
Native TissueChange From Baseline Surgical Pain Scale Normal Score60 Months-0.4 units on a scale
Native TissueChange From Baseline Surgical Pain Scale Normal Score48 Months-0.4 units on a scale
Native TissueChange From Baseline Surgical Pain Scale Normal Score06 Months-0.5 units on a scale
Native TissueChange From Baseline Surgical Pain Scale Normal Score12 Months-0.5 units on a scale
Native TissueChange From Baseline Surgical Pain Scale Normal Score24 Months-0.6 units on a scale
Sacral ColpopexyChange From Baseline Surgical Pain Scale Normal Score12 Months-0.5 units on a scale
Sacral ColpopexyChange From Baseline Surgical Pain Scale Normal Score24 Months-0.8 units on a scale
Sacral ColpopexyChange From Baseline Surgical Pain Scale Normal Score36 Months-0.7 units on a scale
Sacral ColpopexyChange From Baseline Surgical Pain Scale Normal Score06 Months-0.7 units on a scale
Sacral ColpopexyChange From Baseline Surgical Pain Scale Normal Score60 Months-1 units on a scale
Sacral ColpopexyChange From Baseline Surgical Pain Scale Normal Score48 Months-0.6 units on a scale
Transvaginal MeshChange From Baseline Surgical Pain Scale Normal Score60 Months0.5 units on a scale
Transvaginal MeshChange From Baseline Surgical Pain Scale Normal Score48 Months-0.6 units on a scale
Transvaginal MeshChange From Baseline Surgical Pain Scale Normal Score06 Months-0.9 units on a scale
Transvaginal MeshChange From Baseline Surgical Pain Scale Normal Score12 Months-1 units on a scale
Transvaginal MeshChange From Baseline Surgical Pain Scale Normal Score36 Months-0.5 units on a scale
Transvaginal MeshChange From Baseline Surgical Pain Scale Normal Score24 Months-1 units on a scale
Other Pre-specified

Change From Baseline Surgical Pain Scale Rest Score

The Surgical Pain Scale measuring the post-surgical pain experienced by a subject is composed of 4 questions: Pain at Rest (range 0-10), Pain with Normal Activities (range 0-10), Pain with Exercise (range 0-10), and Intensity of Worst Pain (range 0-10). Lower scores indicate better less pain for the Rest subscale, Normal subscale, Exercise Subscale, and Worst Subscale. Change = (Month \[6, 12, 18, 24, and 36\] Score - Baseline Score).

Time frame: 6 months through 60 Months

Population: An modified intent-to-treat (ITT) analysis which included all eligible participants who were randomized, received the randomized procedure, and who provided outcome data after baseline was performed.

ArmMeasureGroupValue (MEAN)
Native TissueChange From Baseline Surgical Pain Scale Rest Score24 Months-0.5 units on a scale
Native TissueChange From Baseline Surgical Pain Scale Rest Score12 Months-0.5 units on a scale
Native TissueChange From Baseline Surgical Pain Scale Rest Score60 Months-0.7 units on a scale
Native TissueChange From Baseline Surgical Pain Scale Rest Score06 Months-0.6 units on a scale
Native TissueChange From Baseline Surgical Pain Scale Rest Score36 Months-0.5 units on a scale
Native TissueChange From Baseline Surgical Pain Scale Rest Score48 Months-0.9 units on a scale
Sacral ColpopexyChange From Baseline Surgical Pain Scale Rest Score36 Months-0.6 units on a scale
Sacral ColpopexyChange From Baseline Surgical Pain Scale Rest Score24 Months-0.4 units on a scale
Sacral ColpopexyChange From Baseline Surgical Pain Scale Rest Score48 Months-0.5 units on a scale
Sacral ColpopexyChange From Baseline Surgical Pain Scale Rest Score60 Months-1.1 units on a scale
Sacral ColpopexyChange From Baseline Surgical Pain Scale Rest Score06 Months-0.5 units on a scale
Sacral ColpopexyChange From Baseline Surgical Pain Scale Rest Score12 Months-0.4 units on a scale
Transvaginal MeshChange From Baseline Surgical Pain Scale Rest Score06 Months-0.7 units on a scale
Transvaginal MeshChange From Baseline Surgical Pain Scale Rest Score48 Months-0.2 units on a scale
Transvaginal MeshChange From Baseline Surgical Pain Scale Rest Score12 Months-0.8 units on a scale
Transvaginal MeshChange From Baseline Surgical Pain Scale Rest Score24 Months-0.6 units on a scale
Transvaginal MeshChange From Baseline Surgical Pain Scale Rest Score60 Months0.2 units on a scale
Transvaginal MeshChange From Baseline Surgical Pain Scale Rest Score36 Months-0.2 units on a scale
Other Pre-specified

Change From Baseline Surgical Pain Scale Worst Score

The Surgical Pain Scale measuring the post-surgical pain experienced by a subject is composed of 4 questions: Pain at Rest (range 0-10), Pain with Normal Activities (range 0-10), Pain with Exercise (range 0-10), and Intensity of Worst Pain (range 0-10). Lower scores indicate better less pain for the Rest subscale, Normal subscale, Exercise Subscale, and Worst Subscale. Change = (Month \[6, 12, 18, 24, and 36\] Score - Baseline Score).

Time frame: 6 months through 60 Months

Population: An modified intent-to-treat (ITT) analysis which included all eligible participants who were randomized, received the randomized procedure, and who provided outcome data after baseline was performed.

ArmMeasureGroupValue (MEAN)
Native TissueChange From Baseline Surgical Pain Scale Worst Score36 Months-0.4 units on a scale
Native TissueChange From Baseline Surgical Pain Scale Worst Score60 Months-0.6 units on a scale
Native TissueChange From Baseline Surgical Pain Scale Worst Score48 Months-0.3 units on a scale
Native TissueChange From Baseline Surgical Pain Scale Worst Score06 Months-0.7 units on a scale
Native TissueChange From Baseline Surgical Pain Scale Worst Score12 Months-0.8 units on a scale
Native TissueChange From Baseline Surgical Pain Scale Worst Score24 Months-0.6 units on a scale
Sacral ColpopexyChange From Baseline Surgical Pain Scale Worst Score60 Months-1.7 units on a scale
Sacral ColpopexyChange From Baseline Surgical Pain Scale Worst Score36 Months-1.1 units on a scale
Sacral ColpopexyChange From Baseline Surgical Pain Scale Worst Score24 Months-1.2 units on a scale
Sacral ColpopexyChange From Baseline Surgical Pain Scale Worst Score06 Months-1.1 units on a scale
Sacral ColpopexyChange From Baseline Surgical Pain Scale Worst Score48 Months-1 units on a scale
Sacral ColpopexyChange From Baseline Surgical Pain Scale Worst Score12 Months-0.9 units on a scale
Transvaginal MeshChange From Baseline Surgical Pain Scale Worst Score60 Months0.8 units on a scale
Transvaginal MeshChange From Baseline Surgical Pain Scale Worst Score12 Months-1.1 units on a scale
Transvaginal MeshChange From Baseline Surgical Pain Scale Worst Score48 Months-0.2 units on a scale
Transvaginal MeshChange From Baseline Surgical Pain Scale Worst Score06 Months-0.9 units on a scale
Transvaginal MeshChange From Baseline Surgical Pain Scale Worst Score24 Months-1 units on a scale
Transvaginal MeshChange From Baseline Surgical Pain Scale Worst Score36 Months-0.4 units on a scale
Other Pre-specified

Change From Baseline UDI Score

The Pelvic Floor Distress Inventory is a 20-question, validated, self-reported instrument used to evaluate pelvic floor symptoms. It consists of an overall scale (range: 0-300) comprised of 3 sub-scales: 1. Pelvic Organ Prolapse Distress Inventory (range: 0-100), 2. Colorectal Anal Distress Inventory (range: 0-100), and 3. Urinary Distress Inventory (range: 0-100). The range of responses for all questions is 1-4 with (1) Not at all, (2) Somewhat, (3) Moderately, and (4), Quite a bit. Subscale scores are calculated by multiplying the mean value of all questions answered by 25 for the subscale. The range of score for each subscale is: 0-100 with 0 (least distress) to 100 (most distress). The PFDI is calculated as the sum of the three subscales. Lower scores indicate better function / fewer symptoms for the PFDI scale, POPDI subscale, CRADI subscale, and UDI subscale. Change from baseline = (Month \[12, 24, 36\] Score - Baseline Score).

Time frame: 6 months through 60 Months

Population: An modified intent-to-treat (ITT) analysis which included all eligible participants who were randomized, received the randomized procedure, and who provided outcome data after baseline was performed.

ArmMeasureGroupValue (MEAN)
Native TissueChange From Baseline UDI Score48 Months-26.9 units on a scale
Native TissueChange From Baseline UDI Score60 Months-27.3 units on a scale
Native TissueChange From Baseline UDI Score36 Months-28 units on a scale
Native TissueChange From Baseline UDI Score12 Months-29.5 units on a scale
Native TissueChange From Baseline UDI Score06 Months-27.3 units on a scale
Native TissueChange From Baseline UDI Score24 Months-26.8 units on a scale
Sacral ColpopexyChange From Baseline UDI Score36 Months-30.2 units on a scale
Sacral ColpopexyChange From Baseline UDI Score60 Months-31.4 units on a scale
Sacral ColpopexyChange From Baseline UDI Score24 Months-29.5 units on a scale
Sacral ColpopexyChange From Baseline UDI Score12 Months-31.2 units on a scale
Sacral ColpopexyChange From Baseline UDI Score48 Months-27.9 units on a scale
Sacral ColpopexyChange From Baseline UDI Score06 Months-29.3 units on a scale
Transvaginal MeshChange From Baseline UDI Score60 Months-22.2 units on a scale
Transvaginal MeshChange From Baseline UDI Score12 Months-26.9 units on a scale
Transvaginal MeshChange From Baseline UDI Score36 Months-28 units on a scale
Transvaginal MeshChange From Baseline UDI Score48 Months-24.1 units on a scale
Transvaginal MeshChange From Baseline UDI Score06 Months-28.2 units on a scale
Transvaginal MeshChange From Baseline UDI Score24 Months-28 units on a scale
Other Pre-specified

Change From Baseline UIQ Score

The Pelvic Floor Impact Questionnaire short form (PFIQ-7) measuring the impact of bladder, bowel, and vaginal symptoms on a woman's daily activities, relationships and emotions is composed of an overall score (range 0-300), 3 subscales (7 questions each): the Urinary Impact Questionnaire (UIQ; range 0-100), the Pelvic Organ Prolapse Impact Questionnaire (POPIQ; range 0-100), and the Colorectal-Anal Impact Questionnaire (CRAIQ; range 0-100). The range of responses on all questions is 0-3 with (0) Not at all ... (3), Quite a bit. Subscale scores are calculated by multiplying the mean value of all answered questions for a scale by 100 divided by 3. The range of scores for each subscale is: 0-100 with 0 (least negative impact) to 100 (most negative impact). The PFIQ is the sum of the three subscales. Lower scores indicate better function / fewer symptoms for the PFIQ score, UIQ score, POPIQ score, and CRAIQ score. Change = (Week \[12, 24\] Score - Baseline Score).

Time frame: 6 months through 60 Months

Population: An modified intent-to-treat (ITT) analysis which included all eligible participants who were randomized, received the randomized procedure, and who provided outcome data after baseline was performed.

ArmMeasureGroupValue (MEAN)
Native TissueChange From Baseline UIQ Score12 Months-17 units on a scale
Native TissueChange From Baseline UIQ Score60 Months-11.5 units on a scale
Native TissueChange From Baseline UIQ Score06 Months-15 units on a scale
Native TissueChange From Baseline UIQ Score48 Months-16.3 units on a scale
Native TissueChange From Baseline UIQ Score36 Months-17.6 units on a scale
Native TissueChange From Baseline UIQ Score24 Months-15.7 units on a scale
Sacral ColpopexyChange From Baseline UIQ Score60 Months-17.8 units on a scale
Sacral ColpopexyChange From Baseline UIQ Score06 Months-18.7 units on a scale
Sacral ColpopexyChange From Baseline UIQ Score12 Months-18.3 units on a scale
Sacral ColpopexyChange From Baseline UIQ Score24 Months-17 units on a scale
Sacral ColpopexyChange From Baseline UIQ Score48 Months-15.9 units on a scale
Sacral ColpopexyChange From Baseline UIQ Score36 Months-17.7 units on a scale
Transvaginal MeshChange From Baseline UIQ Score12 Months-18.5 units on a scale
Transvaginal MeshChange From Baseline UIQ Score06 Months-18.9 units on a scale
Transvaginal MeshChange From Baseline UIQ Score60 Months-8.4 units on a scale
Transvaginal MeshChange From Baseline UIQ Score48 Months-11 units on a scale
Transvaginal MeshChange From Baseline UIQ Score36 Months-16.3 units on a scale
Transvaginal MeshChange From Baseline UIQ Score24 Months-17.8 units on a scale
Other Pre-specified

Number of Participants With PGI-I Reported Improvement

The Patient Global Impression of Improvement (PGI-I) is a patient-reported measure of perceived improvement with treatment, as assessed on a scale of 1 (very much better) to 7 (very much worse). Included here are participants who had improvement as indicated by a rating of 1 (very much better), 2 (much better).

Time frame: 6 months through 60 Months

Population: An modified intent-to-treat (ITT) analysis which included all eligible participants who were randomized, received the randomized procedure, and who provided outcome data after baseline was performed.

ArmMeasureGroupCategoryValue (COUNT_OF_PARTICIPANTS)
Native TissueNumber of Participants With PGI-I Reported Improvement06 MonthsNo improvement16 Participants
Native TissueNumber of Participants With PGI-I Reported Improvement12 MonthsNo improvement9 Participants
Native TissueNumber of Participants With PGI-I Reported Improvement24 MonthsImprovement87 Participants
Native TissueNumber of Participants With PGI-I Reported Improvement24 MonthsNo improvement10 Participants
Native TissueNumber of Participants With PGI-I Reported Improvement36 MonthsImprovement79 Participants
Native TissueNumber of Participants With PGI-I Reported Improvement36 MonthsNo improvement12 Participants
Native TissueNumber of Participants With PGI-I Reported Improvement48 MonthsImprovement58 Participants
Native TissueNumber of Participants With PGI-I Reported Improvement48 MonthsNo improvement15 Participants
Native TissueNumber of Participants With PGI-I Reported Improvement60 MonthsImprovement33 Participants
Native TissueNumber of Participants With PGI-I Reported Improvement60 MonthsNo improvement8 Participants
Native TissueNumber of Participants With PGI-I Reported Improvement06 MonthsImprovement96 Participants
Native TissueNumber of Participants With PGI-I Reported Improvement12 MonthsImprovement101 Participants
Sacral ColpopexyNumber of Participants With PGI-I Reported Improvement60 MonthsImprovement33 Participants
Sacral ColpopexyNumber of Participants With PGI-I Reported Improvement36 MonthsImprovement88 Participants
Sacral ColpopexyNumber of Participants With PGI-I Reported Improvement06 MonthsImprovement108 Participants
Sacral ColpopexyNumber of Participants With PGI-I Reported Improvement36 MonthsNo improvement5 Participants
Sacral ColpopexyNumber of Participants With PGI-I Reported Improvement60 MonthsNo improvement4 Participants
Sacral ColpopexyNumber of Participants With PGI-I Reported Improvement48 MonthsImprovement68 Participants
Sacral ColpopexyNumber of Participants With PGI-I Reported Improvement48 MonthsNo improvement4 Participants
Sacral ColpopexyNumber of Participants With PGI-I Reported Improvement06 MonthsNo improvement6 Participants
Sacral ColpopexyNumber of Participants With PGI-I Reported Improvement12 MonthsImprovement100 Participants
Sacral ColpopexyNumber of Participants With PGI-I Reported Improvement12 MonthsNo improvement8 Participants
Sacral ColpopexyNumber of Participants With PGI-I Reported Improvement24 MonthsImprovement90 Participants
Sacral ColpopexyNumber of Participants With PGI-I Reported Improvement24 MonthsNo improvement5 Participants
Transvaginal MeshNumber of Participants With PGI-I Reported Improvement24 MonthsImprovement97 Participants
Transvaginal MeshNumber of Participants With PGI-I Reported Improvement24 MonthsNo improvement7 Participants
Transvaginal MeshNumber of Participants With PGI-I Reported Improvement60 MonthsImprovement34 Participants
Transvaginal MeshNumber of Participants With PGI-I Reported Improvement12 MonthsNo improvement8 Participants
Transvaginal MeshNumber of Participants With PGI-I Reported Improvement36 MonthsImprovement84 Participants
Transvaginal MeshNumber of Participants With PGI-I Reported Improvement06 MonthsNo improvement11 Participants
Transvaginal MeshNumber of Participants With PGI-I Reported Improvement06 MonthsImprovement98 Participants
Transvaginal MeshNumber of Participants With PGI-I Reported Improvement36 MonthsNo improvement5 Participants
Transvaginal MeshNumber of Participants With PGI-I Reported Improvement12 MonthsImprovement96 Participants
Transvaginal MeshNumber of Participants With PGI-I Reported Improvement48 MonthsNo improvement6 Participants
Transvaginal MeshNumber of Participants With PGI-I Reported Improvement48 MonthsImprovement67 Participants
Transvaginal MeshNumber of Participants With PGI-I Reported Improvement60 MonthsNo improvement3 Participants

Source: ClinicalTrials.gov · Data processed: Sep 16, 2026